Company’s Net Profit in 9MFY26 was reported at Rs. 25.72 crore, Y-o-Y growth of 16 per cent.

Hester Biosciences Limited, one of India’s leading animal health company, manufacturing vaccines and health products has reported standalone net profit of Rs. 10.67 crore for the Q3 FY25-26, rise of 140 per cent as compared to the net profit of Rs. 4.44 crore reported in the third quarter of FY 2024-25. Revenue from operations of the company on the standalone basis for the Q3FY26 was reported at Rs.70.35 crore, up 12 per cent Y-o-Y from Rs. 62.86 crore in Q3FY25. EBITDA for Q3FY26 was reported at Rs. 17.75 crore (EBITDA margin 25 per cent) as against EBITDA of Rs. 10.32 crore (EBITDA margin 16%) in Q3FY25, growth of 72 per cent) Y-o-Y. EPS for Q3 FY26 was Rs. 12.54 per share.

During the quarter, Hester capitalised its fill-finish facility, effectively doubling its drug product capacity. Company also expanded facility enhances manufacturing flexibility, scalability, and readiness to support future growth across domestic and export markets. The company continues to maintain strong operational discipline through controlled overheads, process standardisation, and efficient manpower deployment.

Post the quarter-end, the company received marketing and manufacturing licences for the H9N2 Avian Influenza vaccine, marking an important regulatory milestone and further strengthening Hester’s poultry vaccine portfolio.

Standalone Net Profit for 9MFY26 was reported at Rs. 25.72 crore, up 16 per cent Y-o-Y from Rs. 22.21 crore in the corresponding period last year. EBITDA for nine months of FY26 ended in December 2025 was reported at Rs 44.46 crore (EBITDA margin 22 per cent) as against EBITDA of Rs. 40.95 crore (EBITDA margin 20 per cent) in 9MFY25. Revenue from operations for the first nine months of FY26 was reported at Rs. 198.42 crore as against revenue of Rs. 209.79 crore in 9MFY25.

Way Forward

1.     Q3 FY26 marked a phase of improved execution and capacity strengthening for Hester.

2.     The company remains focused on building a more balanced and resilient business by reducing dependence on tender-based revenues, nationally and internationally, by deepening its presence across commercial, private markets.

3.     Improved placements, stronger market penetration, and disciplined execution are expected to support sustained performance, particularly in the Poultry Healthcare Division.

4.     With the commercialisation of H9N2 vaccine against Avian Influenza in poultry and the expanded fill-finish capacity now operational, the company is well positioned to support future growth while maintaining margin stability and operational discipline.

Poultry Healthcare Division

The Poultry Healthcare Division delivered 32 per cent growth in Q3 FY26 and 17 per centgrowth in 9M FY26, driven by deeper market penetration, improved placements and sustained demand for our vaccines. Enhanced field execution, better distributor coverage, and focused technical engagement with customers also supported higher volumes during the quarter.

Post the quarter-end, the company received marketing and manufacturing licences for the H9N2 Avian Influenza vaccine, marking an important regulatory milestone and further strengthening Hester’s poultry vaccine portfolio.

Animal Healthcare Division

The Animal Healthcare Division recorded a 38 per cent decline in Q3 FY26 and a 40 per cent decline in 9M FY26, primarily due to delays in government-led immunisation programmes in the ruminant segment, particularly PPR and Goat Pox (for immunising against the Lumpy Skin Disease). Having said that, the execution of PPR orders under national immunisation program will commence in February 2026 adding